• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 12, 2022 at 10:52: AM
via A new group of bispecifics targeting CD20 is on the rise in lymphoma, and first-in-class Roche is digging its trench deeper with new updates for Lunsumio and market-nearing glofitamab as potential competition from AbbVie and Regeneron draw near.

article source
 

<



Similar threads

cafead
ASH: Roche offers glimpse of Columvi-Polivy combo&#039;s early lymphoma data as phase 3...
Replies
0
Views
80
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASH: Roche records phase 3 rare disease win ahead of Soliris showdown
Replies
0
Views
141
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASH: Roche&#039;s antibody-drug conjugate Polivy added to chemo-antibody combo boosts...
Replies
0
Views
110
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASH: Roche uncorks eyepopping responses in bispecific test, hoping to add a jewel to its...
Replies
0
Views
162
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASH: Roche bispecific delivers for hard-to-treat lymphoma patients failed by CAR-Ts
Replies
0
Views
136
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote